Christopher Palma
A5017020117- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Viral Infectious Diseases and Gene Expression in Insects
- Phagocytosis and Immune Regulation
- Parvovirus B19 Infection Studies
- COVID-19 and healthcare impacts
- CRISPR and Genetic Engineering
- Sepsis Diagnosis and Treatment
- Renal Diseases and Glomerulopathies
- Trypanosoma species research and implications
- Autoimmune and Inflammatory Disorders Research
- Monoclonal and Polyclonal Antibodies Research
- Systemic Lupus Erythematosus Research
- Systemic Sclerosis and Related Diseases
- Insect symbiosis and bacterial influences
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Virus-based gene therapy research
- Urticaria and Related Conditions
- CAR-T cell therapy research
- Vasculitis and related conditions
- Vector-Borne Animal Diseases
University of Rochester
2019-2023
University of Rochester Medical Center
2021-2022
Johns Hopkins University
2011
Yale University
2006
Importance Immune dysregulation contributes to poorer outcomes in COVID-19. Objective To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added standard care for COVID-19 pneumonia. Design, Setting, and Participants Randomized, double-masked, placebo-controlled clinical trial using a master protocol immunomodulators treatment of participants hospitalized with The results 3 substudies are reported from 95 hospitals at 85 research sites the US Latin America....
Evaluate the safety and efficacy of Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib in COVID-19-associated acute respiratory distress syndrome requiring mechanical ventilation.Phase 3 randomized, double-blind, placebo-controlled trial Ruxolitinib Participants With COVID-19-Associated Acute Respiratory Distress Syndrome Who Require Mechanical Ventilation (RUXCOVID-DEVENT; NCT04377620).Hospitals community-based private or group practices United States (29 sites) Russia (4 sites).Eligible...
Abstract Trypanosoma brucei , a unicellular parasite causing human sleeping sickness and animal nagana, has great impact on the socioeconomic environment of sub‐Saharan Africa. The dynamics are still poorly understood. We have characterized 14 polymorphic di‐, tri‐ tetranucleotide microsatellite loci with perfect repeats (only one motif) exhibiting between five 16 alleles in T. isolates from all over Africa described subspecies. microsatellites will be useful addressing population genetic...
Immune dysregulation contributes to poorer outcomes in severe Covid-19. Immunomodulators targeting various pathways have improved outcomes. We investigated whether infliximab provides benefit over standard of care.We conducted a master protocol investigating immunomodulators for potential treatment participants hospitalized with Covid-19 pneumonia. report results (single dose infusion) versus shared placebo both care. Primary outcome was time recovery by day 29 (28 days after randomization)....
We investigated whether abatacept, a selective costimulation modulator, provides additional benefit when added to standard-of-care for patients hospitalized with Covid-19.We conducted master protocol investigate immunomodulators potential treating Covid-19 and report results abatacept. Intravenous abatacept (one-time dose 10 mg/kg, maximum 1000 mg) plus standard of care (SOC) was compared shared placebo SOC. Primary outcome time-to-recovery by day 28. Key secondary endpoints included 28-day...